Hanmi Science CEO takes charge as Oxford Vacmedix’s Director

Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines has announced the appointment of ChongYoon Lim as a Director of the company. Lim is the Chief Executive Officer (CEO) of Hanmi Science, one of the largest biopharma companies in South Korea and has recently acquired a leading shareholding in Cancer ROP, the principal Series A investor in OVM. He joined Hanmi Pharma in 2000 and was appointed as CEO in 2009, also taking roles as the CEO of Beijing Hanmi and of Hanmi China. In 2007 he established Coree Therapeutics in South Korea. He was responsible for the rapid development of the

Hanmi businesses, including the registration and approval of many new pharmaceutical products and the out-licensing of multiple drug candidates to other global companies. In 2016, Lim became the CEO of Hanmi Science and in 2019 he was appointed the Chairman of the Korea Biotechnology Industry Organisation.